Indaptus Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
INDP$2.90-7.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
Unaudited Condensed Consolidated Statements of Operations
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Operating expenses: | ||||
| Research and development | $1,517,723 | $1,466,037 | $6,495,677 | $4,771,152 |
| General and administrative | 1,130,764 | 1,676,020 | 5,182,132 | 6,423,029 |
| Total operating expenses | 2,648,487 | 3,142,057 | 11,677,809 | 11,194,181 |
| Loss from operations | (2,648,487) | (3,142,057) | (11,677,809) | (11,194,181) |
| Other income, net | 39,088 | 73,021 | 94,764 | 303,201 |
| Change in fair value of convertible promissory notes | (365,718) | - | (1,153,421) | - |
| Net loss | $(2,975,117) | $(3,069,036) | $(12,736,466) | $(10,890,980) |
| Net loss available to common stockholders per share of common stock, basic and diluted* | $(2.98) | $(9.04) | $(18.48) | $(34.53) |
| Weighted average number of shares used in calculating net loss per share, basic and diluted* | 997,038 | 339,659 | 689,174 | 315,451 |
| * | Retroactively restated for one-for-twenty-eight share consolidation on June 27, 2025. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.